Document is current
Any future updates will be listed below
-
Authors
He, Haijun
Ai, Ruixue
Fang, Evandro Fei
Palikaras, Konstantinos
-
Funding
Funding for this research was provided by:
China Scholarship Council
Cure Alzheimer’s Fund
HELSE SØR-ØST
Research Council of Norway
the National Natural Science Foundation of China (81971327)
Akershus University Hospital ((#269901, #261973, #262960)
the Rosa sløyfe/Norwegian Cancer Society & Norwegian Breast Cancer Society (207819)
European Commission (GA101077374-SynaptoMitophagy)
Fondation Santé (19656)
Greece 2.0, National Recovery and Resilience Plan Flagship program (TAEDR-0535850)
- License Information
-
More Information
Article History
Received: 11 December 2024
Accepted: 1 July 2025
First Online: 14 July 2025
Competing interests
: H.H. and K.P. declare no competing interests. E.F.F. is a co-owner of Fang-S Consultation AS (Organization number 931 410 717) and NO-Age AS (Organization number 933 219 127); he has an MTA with LMITO Therapeutics Inc. (South Korea), a CRADA arrangement with ChromaDex (USA), a commercialization agreement with Molecule AG/VITADAO, and MTAs with GeneHarbor (Hong Kong) Biotechnologies Limited and Hong Kong Longevity Science Laboratory (Hong Kong); he is a consultant to MindRank AI (China), NYO3 (Norway), AgeLab (Vitality Nordic AS, Norway), and Hong Kong Longevity Science Laboratory (Hong Kong).
